NCT05661201 2026-03-06
NEROFE and Doxorubicin in KRAS-mutated ST2-positive Solid Tumors
Georgetown University
Phase 1 Recruiting
Clinical Trials
12 trialsNCT05279300 2025-08-11
A Study of CS5001 in Patients With Advanced Solid Tumors and Lymphomas
CStone Pharmaceuticals
Phase 1 Recruiting
NCT03034304 2025-07-24
A Phase I Clinical Study for Evaluating the Safety and Efficacy of MASCT-I in Patients With Advanced Solid Tumors
HRYZ Biotech Co.
Phase 1 Terminated
NCT05785754 2025-06-26
DCSZ11 as a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid Tumors
DynamiCure Biotechnology
Phase 1 Recruiting
NCT00023855 2019-12-13
PS-341 and Doxorubicin in Treating Patients With Advanced Solid Tumors
University of Wisconsin, Madison
Phase 1 Completed
NCT01163903 2015-07-15
Pantoprazole With Doxorubicin for Advanced Cancer Patients With Extension Cohort of Patients With Solid Tumours
University Health Network, Toronto
Phase 1 Completed
NCT01702129 2014-09-09
Anti-EGFR Immunoliposomes in Solid Tumors
University Hospital, Basel, Switzerland
Phase 1 Completed
NCT00008073 2013-12-19
Octreotide and Doxorubicin in Treating Patients With Advanced Cancer
University of Pittsburgh
Phase 1 Completed
NCT00331955 2013-07-02
Vorinostat and Doxorubicin in Treating Patients With Metastatic or Locally Advanced Solid Tumors
National Cancer Institute (NCI)
Phase 1 Completed
NCT00079014 2013-05-16
3-AP and Doxorubicin In Treating Patients With Metastatic or Refractory Solid Tumors
National Cancer Institute (NCI)
Phase 1 Completed
NCT00500422 2013-02-13
Doxil, Gemcitabine, and Velcade (PS341) in Advanced Cancer Patients
M.D. Anderson Cancer Center
Phase 1 Completed
NCT00020124 2012-03-15
Inhaled Doxorubicin in Treating Patients With Advanced Solid Tumors Affecting the Lungs
National Institutes of Health Clinical Center (CC)
Phase 1 Completed